Ensuring glucagon access for people with diabetes: A case example from community pharmacy

Abstract

People with diabetes who are prescribed insulin or who are at high risk of recurrent level 2 or level 3 hypoglycemia should be prescribed glucagon. More than seven million Americans are prescribed insulin and prescriptions for glucagon were filled in 8.3% of people using short-acting insulin, 2.3% of people using long-acting insulin, and 0.4% of people not using insulin. Community pharmacy teams can identify individuals at high risk for hypoglycemia and play an important role in improving access to glucagon. Using Community Pharmacy Enhanced Services Network (CPESN®) USA as a model, we will describe opportunities for community pharmacies to improve glucagon access and patient health outcomes.